ARCHIVES

ODAC Reviews Post-Marketing Studies for Eight Indications

This article is from The Cancer Letter archive.

Vol. 29 No. 08 | February 21, 2003

Download PDF Visit The Full Archive

Related Articles

Alexion In Collaboration With Netherlands Center.

November 30, 2001

High-Dose Chemo, Stem Cell Transplant No Benefit For Node+ Breast Cancer

January 25, 2008

HEW Finally Moves On Distribution Of Chemicals

September 7, 1979

Letters to the Editor: Burzynski: Reviewers Sought To Discredit Antineoplaston Therapy

October 30, 1998

In Brief: Durant To Leave Alabama, Will Become President, Chief Executive Officer At Fox Chase Cancer Center

September 17, 1982

Amgen Agrees To Buy Immunex For $16 Billion In Stock And Cash.

January 25, 2002